A Dividend Aristocrat to Buy That's 39% Undervalued and Yields 5%
The company has increased its dividend for 56 consecutive years.
Source: morningstar.com
Stay updated with breaking news from Value Estimate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The company has increased its dividend for 56 consecutive years.
Many of these dividend-paying stocks are trading at attractive prices.
It’s also among the best value stocks for the long term.
We expect innovation and moats will help the biopharma industry outrun patent expirations.
Notable names are trading at discounted prices.